There are currently phase Ib-II clinical trials evaluating anti-IL-6 blockade combined with ipilimumab and nivolumab in patients with unresectable or metastatic melanoma (NCT03999749) or with anti-Her2 antibodies in Her2 amplified breast cancer (NCT03135171). This evidence concerns the gene ERBB2 and metastatic melanoma.